Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV/AIDS Patients After Highly Active Antiretroviral Therapy (HAART)
Primary Purpose
Acquired Immune Deficiency Syndrome Virus, HIV Infections
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Fuzheng 2
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Acquired Immune Deficiency Syndrome Virus focused on measuring AIDS, complementary therapies, treatment experienced
Eligibility Criteria
Inclusion Criteria:
- HIV antibody-positive, confirmed by Western Blot test
- HIV antibody-positive, confirmed by Western Blot test
- HAART ≥ 12 months
- CD 4 count increased by <100 cells / ul
- HIV RNA <50 c / ml (bDNA);
- Age ≥ 18 years old and ≤ 70 years old
- Voluntary participated in this study, signed informed consent form, and could be followed-up
Exclusion Criteria:
- Serious opportunistic infections were not brought under control (Pneumocystis carinii pneumonia, meningitis, esophageal candidiasis, lymphoma, toxoplasma encephalopathy, tuberculosis, etc.) before the experiment
- Participated in clinical trials of other drugs within one month before the experiment
- Received immunomodulatory treatment within one month before the experiment
- WBC <2 × 10 9 / L, N <1.0 × 10 9 / L, Hb <90g / L, PLT <75 × 10 9 / L,liver and kidney dysfunction (AST, ALT, T-BIL ≥2 times of upper limit of the reference value or creatinine ≥ 2 times of the upper limit of reference value)
- Patients with pancreatitis or active gastric ulcer
- Patients with obvious active diseases in respiratory system, digestive system, circulatory system, blood system, neuroendocrine system, or genitourinary system diseases
- Persons suffering from autoimmune diseases
- Cancer patients which need chemotherapy
- Pregnant or lactating women, and did not use safe contraceptive measures for women of child-bearing age, as well as the male that can not take a reasonable method of contraception in trial period
- Hypersensitive people
- Patients with dysgnosia or language barriers, which can not fully understand the test or cooperate well
Sites / Locations
- Guang'anmen Hospital of China Academy of Chinese Medical SciencesRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Fuzheng 2
Placebo
Arm Description
Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Outcomes
Primary Outcome Measures
Peripheral blood CD3+ CD4+ counts
Secondary Outcome Measures
Immune reconstitution efficiency
Viral load
Clinical symptoms and signs
KPS score
Quality of life score
Side effects of HAART
Safety evaluation
Economic evaluation
Full Information
NCT ID
NCT00974454
First Posted
September 9, 2009
Last Updated
October 28, 2009
Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT00974454
Brief Title
Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV/AIDS Patients After Highly Active Antiretroviral Therapy (HAART)
Official Title
Research on Effect of TCM on Immune Reconstitution of HIV/AIDS Patients After HAART
Study Type
Interventional
2. Study Status
Record Verification Date
September 2009
Overall Recruitment Status
Unknown status
Study Start Date
September 2009 (undefined)
Primary Completion Date
April 2010 (Anticipated)
Study Completion Date
December 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Chinese prescriptions can inhibit viral replication according to the course of viral replication, and the effects is similar to the effect of HAART, and even better than the anti-viral and immune reconstitution of HAART due to its effect on improve immune system function. Over the past decades, many researchers have screened the effective Chinese medicines to treat AIDS.
Detailed Description
There is no record of AIDS in Chinese medicine, modern clinicians hold that AIDS is linked to TCM theory according to its pathogenesis, character of onset and clinical manifestations. As early as more than 2000 years ago, there were records of immune function in TCM. 2 TCM books recorded that "keep vital Qi, the evil will not invade the body "and" the invasion of evil is caused by the deficiency of vital Qi. Vital Qi summarizes the normal immune system function. Vital Qi is the basic material and physiological function which can eliminate the evil, regulating yin and yang and protect the body.
And this is in accordance with defense, homeostasis and surveillance of immune system in western medicine. The knowledge of immunology has guided medical practice in China for more than two thousand years. In response to a variety of immune diseases, there are various immunotherapy such as Yiqi Fuzheng immunotherapy, reinforce kidney therapy, huoxuehuayu therapy and heat-clearing and detoxifying therapy. Throughout the course of AIDS, the evil (HIV) exists and the vital Qi is turning weak gradually. If we adopted a number of intervention measures to assist the body's Vital Qi, Vital Qi will be strengthened and the evil will be weakened. Therefore, TCM will play an important role in improving immune function.
Chinese prescriptions can inhibit viral replication according to the course of viral replication, and the effects is similar to the effect of HAART, and even better than the anti-viral and immune reconstitution of HAART due to its effect on improve immune system function. Over the past decades, many researchers have screened the effective Chinese medicines to treat AIDS.
Researchers screened single Chinese herbs, some extract and the effective components of Chinese medicine and prescriptions. Some study the role of its anti-HIV, some study the role of its regulating immunization function. The former studies have shown that immunization 2 (Fuzheng 2) has wide effect on immune system and it can activate the reticuloendothelial system, macrophage phagocytes and lymphocyte transformation. And it can relieve disorders, imbalance of the immune system caused by HIV infection.
In addition, this prescription can inhibit HIV reverse transcription polymerase enzyme and virus-induced syncytium formation, protect virus-infected cells, and inhibit virus replication in HIV-1 infected cells.
Through the clinical trials, we will evaluate the effect of immune 2 (Fuzheng 2) on immune reconstitution of adult HIV/AIDS patients who have received HAART.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acquired Immune Deficiency Syndrome Virus, HIV Infections
Keywords
AIDS, complementary therapies, treatment experienced
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
180 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fuzheng 2
Arm Type
Active Comparator
Arm Description
Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Intervention Type
Drug
Intervention Name(s)
Fuzheng 2
Intervention Description
Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Primary Outcome Measure Information:
Title
Peripheral blood CD3+ CD4+ counts
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Immune reconstitution efficiency
Time Frame
6 months
Title
Viral load
Time Frame
6 months
Title
Clinical symptoms and signs
Time Frame
6 months
Title
KPS score
Time Frame
6 months
Title
Quality of life score
Time Frame
6 months
Title
Side effects of HAART
Time Frame
6 months
Title
Safety evaluation
Time Frame
6 months
Title
Economic evaluation
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
HIV antibody-positive, confirmed by Western Blot test
HIV antibody-positive, confirmed by Western Blot test
HAART ≥ 12 months
CD 4 count increased by <100 cells / ul
HIV RNA <50 c / ml (bDNA);
Age ≥ 18 years old and ≤ 70 years old
Voluntary participated in this study, signed informed consent form, and could be followed-up
Exclusion Criteria:
Serious opportunistic infections were not brought under control (Pneumocystis carinii pneumonia, meningitis, esophageal candidiasis, lymphoma, toxoplasma encephalopathy, tuberculosis, etc.) before the experiment
Participated in clinical trials of other drugs within one month before the experiment
Received immunomodulatory treatment within one month before the experiment
WBC <2 × 10 9 / L, N <1.0 × 10 9 / L, Hb <90g / L, PLT <75 × 10 9 / L,liver and kidney dysfunction (AST, ALT, T-BIL ≥2 times of upper limit of the reference value or creatinine ≥ 2 times of the upper limit of reference value)
Patients with pancreatitis or active gastric ulcer
Patients with obvious active diseases in respiratory system, digestive system, circulatory system, blood system, neuroendocrine system, or genitourinary system diseases
Persons suffering from autoimmune diseases
Cancer patients which need chemotherapy
Pregnant or lactating women, and did not use safe contraceptive measures for women of child-bearing age, as well as the male that can not take a reasonable method of contraception in trial period
Hypersensitive people
Patients with dysgnosia or language barriers, which can not fully understand the test or cooperate well
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jie Liu, MD
Phone
8610-88001381
Email
dr.liujie@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jie WANG, MD
Organizational Affiliation
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Official's Role
Study Chair
Facility Information:
Facility Name
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100053
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie WANG, MD
Phone
8610-88001381
Email
dr.liujie@163.com
12. IPD Sharing Statement
Learn more about this trial
Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV/AIDS Patients After Highly Active Antiretroviral Therapy (HAART)
We'll reach out to this number within 24 hrs